Cathie Wood Invests $362 Million in CRISPR Therapeutics Amid Promising R&D Developments
ARK Innovation ETF's Cathie Wood has a significant stake of nearly $362 million in CRISPR Therapeutics, with the company developing off-the-shelf gene-editing therapies that could expand beyond patient-specific treatments. These include CAR T-cell therapies like CTX110 and zugocabtagene geleucel (formerly CTX112), currently showing promise in clinical trials for lymphoma and autoimmune diseases.
Topics: ARKK ETF CAR T-cell therapies Cathie Wood CRISPR Therapeutics gene editing